1. Home
  2. Analysis
  3. Jakafi
  4. Asacol

Jakafi and Asacol drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Jakafi (ruxolitinib phosphate) and Asacol (mesalamine). Common drug interactions include anaemia among females and epistaxis among males.

The phase IV clinical study analyzes what interactions people have when they take Jakafi and Asacol. It is created by eHealthMe based on reports of 34 people who take the same drugs from the FDA, and is updated regularly.

What is Jakafi?

Jakafi has active ingredients of ruxolitinib phosphate. It is often used in primary myelofibrosis. eHealthMe is studying from 56,530 Jakafi users. Check the latest studies of Jakafi.

What is Asacol?

Asacol has active ingredients of mesalamine. It is often used in ulcerative colitis. eHealthMe is studying from 20,618 Asacol users. Check the latest studies of Asacol.

On Jul, 13, 2026

34 people who take Jakafi and Asacol together, and have interactions are studied.

Jakafi and Asacol drug interactions.

What are the common drug interactions of Jakafi and Asacol, by gender? *:

female:

  1. Anaemia (lack of blood)
  2. Splenomegaly (enlargement of spleen)
  3. Pneumonia
  4. Pulmonary thrombosis (scarring in the lungs)
  5. Shock hypoglycaemic (a life-threatening condition with symptoms like low blood pressure, weakness, shallow breathing, cold, clammy skin due to less sugar in body)
  6. Thrombosis (formation of a blood clot inside a blood vessel)
  7. Contusion (a type of hematoma of tissue in which capillaries)
  8. Abdominal distension
  9. Heart rate increased
  10. Abdominal discomfort

male:

  1. Epistaxis (bleed from the nose)
  2. Dizziness
  3. Peripheral swelling
  4. Skin injury
  5. Weight decreased
  6. Dry eye (lack of adequate tears)
  7. Dyspnoea (difficult or laboured respiration)
  8. Influenza
  9. Nausea (feeling of having an urge to vomit)
  10. Vertigo

What are the common drug interactions of Jakafi and Asacol, by age (0-1 to 60+)? *:

0-1:

n/a

2-9:

n/a

10-19:

n/a

20-29:

n/a

30-39:

n/a

40-49:

  1. Dizziness
  2. Nausea (feeling of having an urge to vomit)
  3. Vertigo

50-59:

n/a

60+:

  1. Anaemia (lack of blood)
  2. Pneumonia
  3. Dizziness
  4. Duodenal ulcer haemorrhage (bleeding duodenal ulcer)
  5. Fall
  6. Fatigue (feeling of tiredness)
  7. Gastrointestinal angiodysplasia haemorrhagic (a small vascular malformation of the gut with bleeding)
  8. Haemoglobin decreased
  9. Peripheral swelling
  10. Skin injury

What are the existing conditions these people have? *

  1. Polycythaemia Vera (blood disorder in which the bone marrow makes too many red blood cells): 11 people, 32.35%
  2. Urticaria Pigmentosa (skin disease that produces patches of darker skin (lesions) and very bad itching): 2 people, 5.88%
  3. Crohn's Disease (a condition that causes inflammation of the gastrointestinal tract): 2 people, 5.88%
  4. Bone Marrow Failure: 2 people, 5.88%
  5. Aplastic Anemia: 2 people, 5.88%

* Approximation only. Some reports may have incomplete information.

Do you take Jakafi and Asacol?

- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, side effects of, and alternative drugs to the 2 drugs:

Browse all drug interactions of Jakafi and Asacol:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Sub-studies by gender and age:

Female: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Male: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Browse all side effects of Jakafi:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all side effects of Asacol:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all interactions between Jakafi and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all interactions between Asacol and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Related publications that referenced our studies

How the study uses the data?

The study uses data from the FDA. It is based on ruxolitinib phosphate and mesalamine (the active ingredients of Jakafi and Asacol, respectively), and Jakafi and Asacol (the brand names). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.

Recent studies on eHealthMe:

© 2026 eHealthMe.com. All rights reserved. Use of this site constitutes acceptance of eHealthMe.com's terms of service and privacy policy.